236 related articles for article (PubMed ID: 20426425)
21. A cancer-associated aurora A mutant is mislocalized and misregulated due to loss of interaction with TPX2.
Bibby RA; Tang C; Faisal A; Drosopoulos K; Lubbe S; Houlston R; Bayliss R; Linardopoulos S
J Biol Chem; 2009 Nov; 284(48):33177-84. PubMed ID: 19801554
[TBL] [Abstract][Full Text] [Related]
22. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.
Qi W; Spier C; Liu X; Agarwal A; Cooke LS; Persky DO; Chen D; Miller TP; Mahadevan D
Leuk Res; 2013 Apr; 37(4):434-9. PubMed ID: 23153524
[TBL] [Abstract][Full Text] [Related]
23. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
[TBL] [Abstract][Full Text] [Related]
24. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
25. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA
Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB
Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509
[TBL] [Abstract][Full Text] [Related]
27. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
Huck JJ; Zhang M; McDonald A; Bowman D; Hoar KM; Stringer B; Ecsedy J; Manfredi MG; Hyer ML
Mol Cancer Res; 2010 Mar; 8(3):373-84. PubMed ID: 20197380
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
Manfredi MG; Ecsedy JA; Meetze KA; Balani SK; Burenkova O; Chen W; Galvin KM; Hoar KM; Huck JJ; LeRoy PJ; Ray ET; Sells TB; Stringer B; Stroud SG; Vos TJ; Weatherhead GS; Wysong DR; Zhang M; Bolen JB; Claiborne CF
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4106-11. PubMed ID: 17360485
[TBL] [Abstract][Full Text] [Related]
29. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
Kaestner P; Stolz A; Bastians H
Mol Cancer Ther; 2009 Jul; 8(7):2046-56. PubMed ID: 19584233
[TBL] [Abstract][Full Text] [Related]
30. The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Hong X; O'Donnell JP; Salazar CR; Van Brocklyn JR; Barnett KD; Pearl DK; deCarvalho AC; Ecsedy JA; Brown SL; Mikkelsen T; Lehman NL
Cancer Chemother Pharmacol; 2014 May; 73(5):983-90. PubMed ID: 24627220
[TBL] [Abstract][Full Text] [Related]
31. The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy.
Asteriti IA; Di Cesare E; De Mattia F; Hilsenstein V; Neumann B; Cundari E; Lavia P; Guarguaglini G
Oncotarget; 2014 Aug; 5(15):6229-42. PubMed ID: 25153724
[TBL] [Abstract][Full Text] [Related]
32. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
Wang S; Midgley CA; Scaërou F; Grabarek JB; Griffiths G; Jackson W; Kontopidis G; McClue SJ; McInnes C; Meades C; Mezna M; Plater A; Stuart I; Thomas MP; Wood G; Clarke RG; Blake DG; Zheleva DI; Lane DP; Jackson RC; Glover DM; Fischer PM
J Med Chem; 2010 Jun; 53(11):4367-78. PubMed ID: 20462263
[TBL] [Abstract][Full Text] [Related]
33. Determinants for Aurora-A activation and Aurora-B discrimination by TPX2.
Bayliss R; Sardon T; Ebert J; Lindner D; Vernos I; Conti E
Cell Cycle; 2004 Apr; 3(4):404-7. PubMed ID: 14752279
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.
Carol H; Boehm I; Reynolds CP; Kang MH; Maris JM; Morton CL; Gorlick R; Kolb EA; Keir ST; Wu J; Wozniak AE; Yang Y; Manfredi M; Ecsedy J; Wang J; Neale G; Houghton PJ; Smith MA; Lock RB
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1291-304. PubMed ID: 21448591
[TBL] [Abstract][Full Text] [Related]
35. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells.
Jayanthan A; Hofmann B; Meier-Stephenson V; Perinpanayagam M; Dunn SE; Boklan J; Trippett TM; Truong TH; Narendran A
J Pediatr Hematol Oncol; 2019 Aug; 41(6):e359-e370. PubMed ID: 30702467
[TBL] [Abstract][Full Text] [Related]
36. Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
Tuccilli C; Baldini E; Prinzi N; Morrone S; Sorrenti S; Filippini A; Catania A; Alessandrini S; Rendina R; Coccaro C; D'Armiento M; Ulisse S
Endocrine; 2016 May; 52(2):287-95. PubMed ID: 26215279
[TBL] [Abstract][Full Text] [Related]
37. Regulation of Xenopus Aurora A activation by TPX2.
Eyers PA; Maller JL
J Biol Chem; 2004 Mar; 279(10):9008-15. PubMed ID: 14701852
[TBL] [Abstract][Full Text] [Related]
38. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
Chowdhury A; Chowdhury S; Tsai MY
Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
[TBL] [Abstract][Full Text] [Related]
39. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.
Dar AA; Belkhiri A; Ecsedy J; Zaika A; El-Rifai W
Cancer Res; 2008 Nov; 68(21):8998-9004. PubMed ID: 18974145
[TBL] [Abstract][Full Text] [Related]
40. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Muscal JA; Scorsone KA; Zhang L; Ecsedy JA; Berg SL
Invest New Drugs; 2013 Feb; 31(1):39-45. PubMed ID: 22669335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
